Pituitary Adenoma 1, Acth-Secreting Clinical Trial
Official title:
Effects of Pituitary Adenoma Resection on Serum Lipid Level
| NCT number | NCT04021212 |
| Other study ID # | 20190712 |
| Secondary ID | |
| Status | Recruiting |
| Phase | |
| First received | |
| Last updated | |
| Start date | September 1, 2020 |
| Est. completion date | June 2024 |
Pituitary adenomas are usually benign monoclonal neoplasms caused by a mixture of pituicyte alterations together with a changed endocrine and paracrine regulatory milieu. Thus, it can cause serious health problems such as abnormal target organ function, pain, disability and even death. In clinical practice, we found many patients with pituitary adenomas are usually accompanied by hyperlipidemia, which is the main cause of cardiovascular diseases. However, it has been unclear if there is an association between pituitary adenomas and serum lipid profile. In the present study, we aim to focus on the patients with pituitary adenomas and their lipid profile before and after operation including first occurrence and recurrence.
| Status | Recruiting |
| Enrollment | 1000 |
| Est. completion date | June 2024 |
| Est. primary completion date | June 2024 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | N/A and older |
| Eligibility | Inclusion Criteria: 1. Patients diagnosed with pituitary adenomas 2. All adenomas were resected by transsphenoidal surgery and identified by histological diagnoses. Exclusion Criteria: 1. Missing vital data, such as age, gender, serum lipid profile, pathology reports; 2. Complications or conditions that affect pituitary status and lipid metabolism, such as pregnancy, malignant adenomas or severe hepatic or renal dysfunction and 3. Use of any medication that affects the pituitary or lipid metabolism, including statins, fibrates, thyroid hormones, anti-thyroid drugs, iodine, amiodarone, alemtuzumab, lithium, tyrosine kinase inhibitors, interferon, estrogens, androgens,glucocorticoids, nonsteroidal anti-inflammatory drugs, antiepileptic drugs, rifampicin, furosemide, heparin or ß-adrenoceptor blockers in the past 3 months. |
| Country | Name | City | State |
|---|---|---|---|
| China | Shandong Provincial Hospital | Jinan | Shandong |
| Lead Sponsor | Collaborator |
|---|---|
| Shandong Provincial Hospital |
China,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change in serum lipid levels | Measured at pre-operative and 6 months after operation |